Fundraising Fox

Rarecyte

Seattle, US · Delaware corporation · 5 known investors

Founders & leadership

RS
Ronald SeubertNamed on SEC filing
EC
Evan CastigliaNamed on SEC filing
JVJoseph Victor
Joseph VictorNamed on SEC filingVenture Advisor at 5AM Ventures
FW
Frank WitneyNamed on SEC filing
EK
Eric KaldjianNamed on SEC filing

Board

RSRobert Shepler
Robert SheplerinBoard directorPartner Emeritus at Telegraph Hill Partners
BDBrian Daniels
Brian DanielsinBoard directorVenture Partner at 5AM Ventures

Investors · 5

5AM VenturesBoston · $100K – $4M
Arboretum VenturesAnn Arbor · $5M – $15Mvia Jan Garfinkle · board
F-Prime CapitalCambridge · $3M – $10Mvia Robert Weisskoff · board
Sofinnova VenturesreportedMenlo Park · $100K – $15Mvia David Kabakoff · board
Telegraph Hill PartnersreportedSan Francisco · $2M – $8Mvia Robert Shepler · board

Reported raises · per SEC filings

Form D private placements

$79.8M disclosed across 5 rounds · 2017–2023

▶$13.2MraisedJul 2023 · 19 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • David KabakoffDirector
  • Ronald SeubertDirector
  • Robert WeisskoffDirector
  • Daniel MarshakDirector
  • Jan GarfinkleDirector
  • Andrew SchwabDirector
  • Stephen ReichenbachExecutive Officer
  • Joseph J. Victor Jr.Executive Officer, Director
Offering amount
$35.7M
Amount sold
$13.2M
First sale
Jul 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$24MraisedSep 2021 · 27 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew SchwabDirector
  • Jan GarfinkleDirector
  • Daniel MarshakDirector
  • Ronald SeubertDirector
  • Robert WeisskoffDirector
  • David KabakoffDirector
  • Joseph J. Victor Jr.Executive Officer, Director
Offering amount
$24M
Amount sold
$24M
First sale
Aug 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$22.2MraisedDec 2019 · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Andrew SchwabDirector
  • David KabakoffDirector
  • Ronald SeubertDirector
  • Jim CooperExecutive Officer
  • Joseph J. Victor Jr.Executive Officer, Director
  • Frank WitneyDirector
Offering amount
$22.2M
Amount sold
$22.2M
First sale
Dec 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedMay 2018 · 1 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Brian DanielsDirector
  • Eric KaldjianExecutive Officer
  • Robert SheplerDirector
  • Ronald SeubertExecutive Officer, Director, Promoter
  • Joseph VictorExecutive Officer, Director
  • Frank WitneyDirector
Offering amount
$5M
Amount sold
$5M
First sale
May 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$15.4MraisedAug 2017 · 9 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert SheplerDirector
  • Ronald SeubertExecutive Officer, Director, Promoter
  • Evan CastigliaExecutive Officer
  • Brian DanielsDirector
  • Joseph VictorExecutive Officer, Director
  • Frank WitneyDirector
  • Eric KaldjianExecutive Officer
Offering amount
$16.3M
Amount sold
$15.4M
First sale
Jul 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Incyte Corporation31 shared keywordsIncyte is a global biopharmaceutical company that develops medicines across hematology, oncology, and inflammation and autoimmunity, with clinical programs spanning areas such as dermatology. It focuses on research and development of treatments for patients.

Companies competing with Rarecyte for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 3 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2020$2M
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2018$223.8K
National Institutes of Health (NIH)National Institutes of HealthPhase I2014$598.9K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

Who are Rarecyte's investors?
Rarecyte's investors include 5AM Ventures, Arboretum Ventures, F-Prime Capital, Sofinnova Ventures, Telegraph Hill Partners.
How much funding has Rarecyte raised?
Rarecyte has disclosed $79.8M raised across 5 rounds.
Where is Rarecyte headquartered?
Rarecyte is headquartered in Seattle, US.